Shenglong Zhu

Prof. Shenglong Zhu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
XJXuan Jiang
Xuan Jiang
SJSiyu Ji
Siyu Ji
FYFenglai Yuan
Fenglai Yuan
TLTushuai Li
Tushuai Li
SCSiyuan Cui
Siyuan Cui
Shenglong ZhuShenglong Zhu
Shenglong Zhu
Background: Sarcopenia, the age‐related decline in skeletal muscle mass and function, diminishes life quality in elderly people. Improving the capacity of skeletal muscle differentiation is expected to counteract sarcopenia. However, the mechanisms underlying skeletal muscle differentiation are complex, and effective therapeutic targets are largely unknown.Methods: The human Gene Expression Omnibus database, aged mice and primary skeletal muscle cells were used to assess the expression level of pyruvate dehydrogenase B (PDHB) in human and mouse aged state. d‐Galactose (d‐gal)‐induced sarcopenia mouse model and two classic cell models (C2C12 and HSkMC) were used to assess the myogenic effect of PDHB and the underlying mechanisms via immunocytochemistry, western blotting, quantitative real‐time polymerase chain reaction, RNA interference or overexpression, dual‐luciferase reporter assay, RNA sequencing and untargeted metabolomics.Results: We identified that a novel target PDHB promoted myogenic differentiation. PDHB expression decreased in aged mouse muscle relative to the young state (−50% of mRNA level, P < 0.01) and increased during mouse and primary human muscle cell differentiation (+3.97‐fold, P < 0.001 and +3.79‐fold, P < 0.001). Knockdown or overexpression of PDHB modulated the expression of genes related to muscle differentiation, namely, myogenic factor 5 (Myf5) (−46%, P < 0.01 and −27%, P < 0.05; +1.8‐fold, P < 0.01), myogenic differentiation (MyoD) (−55%, P < 0.001 and −34%, P < 0.01; +2.27‐fold, P < 0.001), myogenin (MyoG) (−60%, P < 0.001 and −70%, P < 0.001; +5.46‐fold, P < 0.001) and myosin heavy chain (MyHC) (−70%, P < 0.001 and −69%, P < 0.001; +3.44‐fold, P < 0.001) in both C2C12 cells and HSkMC. Metabolomic and transcriptomic analyses revealed that PDHB knockdown suppressed pyruvate metabolism (P < 0.001) and up‐regulated ariadne RBR E3 ubiquitin protein ligase 2 (Arih2) (+7.23‐fold, P < 0.001) in cellular catabolic pathways. The role of forkhead box P1 (FoxP1) (+4.18‐fold, P < 0.001)‐mediated Arih2 transcription was the key downstream regulator of PDHB in muscle differentiation. PDHB overexpression improved d‐gal‐induced muscle atrophy in mice, which was characterized by significant increases in grip strength, muscle mass and mean muscle cross‐sectional area (1.19‐fold to 1.5‐fold, P < 0.01, P < 0.05 and P < 0.001).Conclusions: The comprehensive results show that PDHB plays a sarcoprotective role by suppressing the FoxP1–Arih2 axis and may serve as a therapeutic target in sarcopenia.

25 March 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
SCSiyuan Cui
Siyuan Cui
XCXin Chen
Xin Chen
JLJiayu Li
Jiayu Li
WWWei Wang
Wei Wang
DMDeqi Meng
Deqi Meng
SSShiwei Shen
Shiwei Shen
Background: The incidence of diabetic kidney disease (DKD) continues to rapidly increase, with limited available treatment options. One of the hallmarks of DKD is persistent inflammation, but the underlying molecular mechanisms of early diabetic kidney injury remain poorly understood. C-X-C chemokine receptor 2 (CXCR2), plays an important role in the progression of inflammation-related vascular diseases and may bridge between glomerular endothelium and persistent inflammation in DKD. Methods: Multiple methods were employed to assess the expression levels of CXCR2 and its ligands, as well as renal inflammatory response and endothelial glycocalyx shedding in patients with DKD. The effects of CXCR2 on glycocalyx shedding, and persistent renal inflammation was examined in a type 2 diabetic mouse model with Cxcr2 knockout specifically in endothelial cells (DKD-Cxcr2eCKO mice), as well as in glomerular endothelial cells (GECs), cultured in high glucose conditions. Results: CXCR2 was associated with early renal decline in DKD patients, and endothelial-specific knockout of CXCR2 significantly improved renal function in DKD mice, reduced inflammatory cell infiltration, and simultaneously decreased the expression of proinflammatory factors and chemokines in renal tissue. In DKD conditions, glycocalyx shedding was suppressed in endothelial Cxcr2 knockout mice compared to Cxcr2L/L mice. Modulating CXCR2 expression also affected high glucose-induced inflammation and glycocalyx shedding in GECs. Mechanistically, CXCR2 deficiency inhibited the activation of NF-κB signaling, thereby regulating inflammation, restoring the endothelial glycocalyx, and alleviating DKD. Conclusions: Taken together, under DKD conditions, activation of CXCR2 exacerbates inflammation through regulation of the NF-κB pathway, leading to endothelial glycocalyx shedding and deteriorating renal function. Endothelial CXCR2 deficiency has a protective role in inflammation and glycocalyx dysfunction, suggesting its potential as a promising therapeutic target for DKD treatment.

30 September 2023 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
YKYulin Kong
Yulin Kong
XWXia Wang
Xia Wang
ZWZhe Wang
Zhe Wang
CTChunlei Tang
Chunlei Tang
Shenglong ZhuShenglong Zhu
Shenglong Zhu
Due to the complexity and incomplete understanding of the crosstalk between liver and adipose tissue, especially the processes of hepatic lipogenesis and adipogenic differentiation, there are currently no effective drugs for the treatment of nonalcoholic fatty liver disease (NAFLD). Stearoyl-coenzyme A desaturase 1 (SCD1), which is abundantly expressed in liver and adipose tissue, may mediate the cross-talk between liver and adipose tissue. Thus, it is essential to develop specific SCD1 inhibitors that target the liver-adipose axis. Herein, we identified a novel SCD1 inhibitor, E6446, through a high-throughput virtual screen. E6646 significantly inhibited adipogenic differentiation and hepatic lipogenesis via SCD1-ATF3 signaling. The SPR results showed that E6446 had a strong interaction ability with SCD1 (KD:4.61 μM). Additionally, E6646 significantly decreased hepatic steatosis, hepatic lipid droplet accumulation and insulin resistance in high-fat diet (HFD)-fed mice. Taken together, our findings not only suggest that E6446 can serve as a new, safe and highly effective anti-NAFLD agent for future clinical use but also provide a molecular basis for the future development of SCD1 inhibitors that inhibit both adipogenic differentiation and hepatic lipogenesis.

8 July 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
TLTushuai Li
Tushuai Li
ZLZhihong Liu
Zhihong Liu
XFXiao Fu
Xiao Fu
YCYongquan Chen
Yongquan Chen
Shenglong ZhuShenglong Zhu
Shenglong Zhu
JZJie Zhang
Jie Zhang

13 January 2025 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
TZTingting Zhang
Tingting Zhang
WWWei Wang
Wei Wang
JLJiayu Li
Jiayu Li
XYXianlong Ye
Xianlong Ye
ZWZhe Wang
Zhe Wang
Shenglong ZhuShenglong Zhu
Shenglong Zhu

21 October 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YJYao Jiang
Yao Jiang
WWWei Wang
Wei Wang
HWHui Wang
Hui Wang
XZXiaoru Zhang
Xiaoru Zhang
YKYuling Kong
Yuling Kong
Shenglong ZhuShenglong Zhu
Shenglong Zhu